Brennan to chair PhRMA board, with Kindler waiting in the wings

Share this article:
David Brennan
David Brennan
PhRMA's board of directors elected AstraZeneca chief David Brennan as this year's board chairman and Pfizer chairman and CEO Jeff Kindler chairman-elect. Johnson & Johnson's David Norton, company group chairman, worldwide commercial and operations, Pharmaceuticals Group, was elected board treasurer.

Brennan succeeds Merck president and CEO Richard Clark as PhRMA chairman. The votes came at PhRMA's annual meeting in Washington, DC.

In a statement, Clark said: “The PhRMA member companies accomplished much this pas year. We strengthened our marketing code, tightened our DTC advertising principles and voiced strong support of transparency of company interactions with physicians.”

The agenda for the meeting included discussion of policy issues, including healthcare reform and global intellectual property law, as well as medical innovation.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...